23
Apr
GM2 Gangliosidosis Community Response to the FDA regarding AQNEURSA
You can read our letter to the FDA by clicking on the
Read more
16
Sep
The CATS Foundation’s “Spot the Stop” Campaign Wins Bronze at PM Society Digital Awards
We’re incredibly proud to announce that our Spot the Stop campaign, developed in collaboration
Read more
16
Jul
Azafaros press release: Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C
We are pleased to share the latest press release from Azafaros related
Read more
15
Jul
New podcast episode: Rare Revelations – of a IMD Consultant
The latest edition of the Rare Revelations podcast featured Dr María Jose
Read more
12
Jul
Third Sector Award Nomination – Communications Campaign Of The Year
We are very very very happy to share that our “Spot the
Read more
23
May
New podcast episode: Rare Revelations – of Late Onset Sandhoff Disease
The latest edition of the Rare Revelations podcast featured Josh who talked
Read more
25
Apr
Sanofi Press Release: Sanofi’s AMETHIST trial for GM2 gangliosidosis discontinued
Today it was announced by Sanofi that the AMETHIST phase 3 study of venglustat
Read more
07
Mar
New podcast episode: Rare Revelations – Rare Disease Day Edition featuring Patricia Durao
In the latest episode of the CATS Foundation Rare Revelations podcast, listeners
Read more
22
Feb
The CATS Foundation at the Externally-Led, Patient-Focused Drug Development (EL-PFDD) Meeting for GM2
Last week, the Cure & Action for Tay-Sachs (CATS) Foundation had the incredible opportunity
Read more